On May, 10 Analysts See $0.17 EPS for Global Medical REIT Inc. (GMRE)

April 17, 2018 - By Darrel Chase

Global Medical REIT Inc. (NYSE:GMRE) Corporate Logo

On May, 10 WallStreet awaited Global Medical REIT Inc. (NYSE:GMRE)’s earnings release, according to Faxor. Analysts forecast 750.00 % diference or $0.17 from the $0.02 EPS from 2017. If reported the P/E will be 11.10 with $3.75M profit. 13.33 % EPS growth is what analysts predict. $0.15 earnings per share was revealed for last [previous quarter]. GMRE reached $7.55 on during the last trading session after $0.24 change.Global Medical REIT Inc. is downtrending after having declined 20.98% since April 17, 2017. GMRE has 333,386 volume or 120.21% up from normal. GMRE underperformed by 32.53% the S&P 500.

Global Medical REIT Inc. (NYSE:GMRE) Ratings Coverage

In total 2 analysts cover Global Medical REIT (NYSE:GMRE). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NYSE:GMRE)’s analyst reports since November 10, 2017 according to StockzIntelligence Inc. On Monday, November 13 the firm earned “Buy” rating by Cantor Fitzgerald.

Global Medical REIT Inc. is a Maryland corporation engaged primarily in the acquisition of licensed, state-of-the-art, purpose-built healthcare facilities and the leasing of these facilities to strong clinical operators with leading market share.The company has $166.35 million market cap. The Company's strategy is to produce increasing, reliable rental revenue by expanding its portfolio, and leasing its healthcare facilities to market-leading operators under long-term triple-net leases.Currently it has negative earnings. The Company's management team has significant healthcare, real estate and public real estate investment trust, or REIT, experience and has long-established relationships with a wide range of healthcare providers.

Global Medical REIT Inc. (NYSE:GMRE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.